PD Dr. Michael Erdmann

Department of Dermatology

Phase i study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma (2025) Eigentler T, Thomas I, Samoylenko I, Erdmann M, Heinzerling L, Ochsenreither S, Krauss J, et al. Journal article Discordance, accuracy and reproducibility study of pathologists' diagnosis of melanoma and melanocytic tumors (2025) Haggenmüller S, Wies C, Abels J, Winterstein JT, Heinlein L, Nogueira Garcia C, Utikal JS, et al. Journal article Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care (2024) Heinlein L, Maron RC, Hekler A, Haggenmüller S, Wies C, Utikal JS, Meier F, et al. Journal article Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study (2024) Beckmann M, Schlüter J, Erdmann M, Kramer R, Cunningham S, Hackstein H, Zimmermann R, Heinzerling L Journal article Influence of the Immune Checkpoint Inhibitors on the Hemostatic Potential of Blood Plasma (2024) Patalakh I, Wandersee A, Schlüter J, Erdmann M, Hackstein H, Cunningham S Journal article, Original article Gleichzeitiges Auftreten zweier malignomverdächtiger Hautveränderungen (2024) Kaufmann M, Erdmann M, Schliep S, Voskens C, Berking C, Bauerschmitz J Journal article Spatial cell graph analysis reveals skin tissue organization characteristic for cutaneous T cell lymphoma (2024) Sarkar S, Möller A, Hartebrodt A, Erdmann M, Ostalecki C, Baur A, Blumenthal DB Journal article, Original article Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary (2024) Persa OD, Cecile Hassel J, Steeb T, Erdmann M, Karimi B, Stege H, Klespe KC, et al. Journal article Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events (2024) Koch E, Petzold A, Dippel E, Erdmann M, Gesierich A, Gutzmer R, Hassel JC, et al. Journal article Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. (2024) Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, et al. Journal article